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Dear Editor,
Chronic Hepatitis B virus (HBV) infection is the most 
frequent cause of liver disease and hepatocellular car-
cinoma (HCC) worldwide, with most cases occurring in 
resource-limited settings [3]. Early diagnosis is critical in 
reducing hepatitis-related morbidity and mortality. Ironi-
cally, regions of the world with the largest HBV burden 
(i.e. Africa) are the regions with suboptimal laboratory 
infrastructure, leading to lack of diagnosis [4]. Past studies 
of HBV rapid tests have shown highly variable results and 
elevated costs for these tests make them often unafford-
able in resource-limited regions [1, 2]. We evaluated the 
efficacy of low-cost rapid diagnostic tests (RDTs) for HBV 
in Europe, Africa, and South America. 
We performed an external validation of RDTs designed 
for the detection of various HBV serological markers 
(PRECHEK Bio. Inc., Korea). These RDTs were selected 
because of their low cost (approximately 7–28% of the 
cost of WHO-recommended RDTs) and their ability to 
be used for point-of-care diagnostics. These RDTs are 
immunochromatographic assays in which monoclonal 
antibodies against specific antigens or antibodies are 
immobilized on the test line of a nitrocellulose mem-
brane pad. In positive tests, as serum/blood is added, the 
antigen-antibody complex migrates towards the test zone 
(T) where it is captured by immobilized antibodies, form-
ing a visible line. In negative tests, the antigen or antibody 
is absent and there is no visible line.
HBV serological markers tested included HBV-
surface antigen (HBsAg) HBV-surface antigen antibody 
(anti-HBsAb), HBV E antigen (HBeAg) and HBV E antibody 
(anti-HBeAb). Serum and whole-blood samples used for 
testing were obtained from repositories (stored at –80C) 
in hospitals in the Netherlands, Argentina, and Ethiopia. 
Testing was discontinued in RDTs that performed poorly 
during initial assessment. The performance of RDTs was 
assessed by ROC curve analysis, using the local diagnos-
tic standard as the reference test (Argentina: ARCHITECT 
Reagent kits [Abbott, Germany]; Netherlands: LIAISON XL 
system [Diasorin, Italy]; Ethiopia: Onsite Rapid Test [CTK 
Biotech, USA]). Statistical analyses were performed using 
STATA v15.1 (Statacorp, College Station, TX). 
A total of 200 unique serum and whole-blood samples 
were tested using RDTs. The median age of patients was 
40 years (IQR 31–50) and 67% were male. HBV genotypes 
A-F were tested. The HBsAg serum strip had a sensitivity 
and specificity of 100%. The median HBsAg level of 
tested samples (in those available) was 2800 IU/mL 
(range: 150–110,000). The anti-HBeAb serum cassette 
had a sensitivity of 80% and a specificity of 100%. The 
HBsAg whole-blood cassette and strip had specificities 
of 100%, but sensitivities of 56% and 45%, respectively. 
The anti-HBsAb serum cassette had a sensitivity of 57% 
and a specificity of 93%. The anti-HBsAb serum strip had 
a sensitivity of 20% and a specificity of 100%. The HBeAg 
serum strip had a sensitivity of 81% and a specificity of 
67%. The median HBeAg level of tested samples (in those 
available) was 2806 IU/mL (range: 1952–3149). Specific 
RDT performance is available in Table 1.
The HBsAg serum strip RDT demonstrated optimal 
sensitivity and specificity in the three different continents, 
indicating that it can reliably diagnose HBV in various 
populations with different genotypes. The anti-HBeAb 
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Chronic Hepatitis B (HBV) is the most important cause of liver disease worldwide. There is a need for 
low-cost tests to aid in diagnosis and management of HBV infection in resource-limited settings. We 
evaluated the utility of several rapid diagnostic tests (RDT) in three different continents (Europe, South 
America, Africa). The HBsAg RDT showed optimal sensitivity and specificity. The anti-HBeAb RDT showed 
acceptable sensitivity and excellent specificity. Our results suggest that these RDTs could be used for 
screening and management of HBV.
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RDT showed acceptable sensitivity and excellent speci-
ficity, making it useful to differentiate HBeAb status. 
Overall, whole-blood HBsAg and serum anti-HBsAb kits 
performed poorly, as they were specific but insufficiently 
sensitive to be clinically useful for screening. The serum 
HBeAg kits demonstrated acceptable sensitivity, but poor 
specificity, making them unlikely to be useful in the 
clinical setting. Our results suggest that HBsAg and anti-
HBeAb serum RDTS are reliable and, in conjunction with 
alanine aminotransferase levels (ALTs), can be useful for 
diagnosis, as well as informing the need for treatment in 
resource-limited settings. 
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Table 1: Rapid Diagnostic Test Performance.
Test Type (Catalog 
Number)
Number1 
Tested (T/P/N)
Test Site2
(A/E/N)
Age3 Male Sensitivity Specificity
HBsAg Serum Strip
(HBV 211)
81/55/26 A/E/N 39 74% 100% 100%
HBsAg WB Cass.
(HBV 214)
23/16/7 A/N 43 70% 56% 100%
HBsAg WB Strip
(HBV 213)
13/11/2 A/N 42 54% 45% 100%
Anti-HBsAb Serum Cass.
(HBV 222)
38/23/15 N 52 58% 57% 93%
Anti-HBsAb Serum Strip
(HBV 221)
46/20/26 N 38 80% 20% 100%
Anti-HBeAb Serum Cass.
(HBV 232)
64/20/44 N 37 63% 80% 100%
HBeAg Serum Strip
(HBV 242)
27/16/11 A/N 39 81% 82% 67%
1 T = total, P = known positive, N = known negative; 2 A = Argentina, E = Ethiopia, N = Netherlands; 3 Median age. HBsAg, hepatitis B 
surface antigen; anti-HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e antigen; Cass., cassette; WB, whole-blood.
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